In addition, susceptibility genes for CVD (such as APOE, and low-density lipoprotein receptor) are associated with elevated risks of cardiovascular complications among patients with MASLD/NAFLD.[69–76] These insights offer novel perspectives on diagnosing, treating, and preventing MASLD/NAFLD and related cardiovascular disorders. The gene discussed is VLDLR; the disease is metabolic dysfunction-associated steatotic liver disease.